Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 known ✓ | P0DMS8 | 1/20 | 0.32 |
| ▸ | ATP4A known ✓ | P20648 | 1/20 | 0.32 |
| ▸ | ADORA1 known ✓ | P30542 | 1/20 | 0.32 |
| ▸ | ATP4B known ✓ | P51164 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 3/20 | 0.32 |
| ▸ | WDR5 | P61964 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | ENGASE | Q8NFI3 | 2/20 | 0.32 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5763751 | 0.94 | MAPT (0.37) | MAPTEGFRNPC1CYP1A2CYP3A4 | |
| SCHEMBL5763768 | 0.94 | MAPT (0.37) | MAPTEGFRNPC1CYP1A2CYP3A4 | |
| SCHEMBL5765352 | 0.89 | MAPT (0.42) | MAPTEGFRNPC1CYP1A2CYP3A4 | |
| SCHEMBL6484319 | 0.88 | MAPT (0.37) | MAPTEGFRNPC1CYP1A2CYP3A4 | |
| SCHEMBL5761303 | 0.88 | MAPT (0.38) | MAPTEGFRNPC1CYP1A2CYP3A4 | |
| SCHEMBL5760950 | 0.86 | MAPT (0.35) | MAPTEGFRNPC1CYP1A2CYP3A4 | |
| SCHEMBL5765350 | 0.85 | MAPT (0.42) | MAPTEGFRNPC1CYP1A2CYP3A4 | |
| SCHEMBL5765367 | 0.85 | MAPT (0.42) | MAPTEGFRNPC1CYP1A2CYP3A4 | |
| SCHEMBL5760528 | 0.85 | HPGD (0.34) | MAPTEGFRHPGDALDH1A1 | |
| SCHEMBL5762450 | 0.84 | MAPT (0.39) | MAPTEGFRNPC1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1556371-B1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PRODRUGS OF PROTON PUMP INHIBITOR | WINSTON PHARMACEUTICALS LLC (US) | 2006-04-19 | — | — | EP | disclosed |
| US-20050182101-A1 | Prodrugs of proton pump inhibitors | GARST MICHAEL (US) | 2005-08-18 | — | — | US | disclosed |
| US-20050143423-A1 | Prodrugs of proton pump inhibitors background of the invention | GARST MICHAEL (US) | 2005-06-30 | — | — | US | disclosed |
| US-6897227-B2 | Prodrugs of proton pump inhibitors | Winston Pharmaceuticals, Inc. (US) | 2005-05-24 | — | — | US | disclosed |
| US-20040102484-A1 | Prodrugs of proton pump inhibitors | ALEVIUM PHARMACEUTICALS, INC. | 2004-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102484-A1 | Prodrugs of proton pump inhibitors | ABCB11, SLC10A2, SI | ADORA3 755/4885ATP4A 41/4885ADORA1 386/4885 |
| US-20050143423-A1 | Prodrugs of proton pump inhibitors background of the invention | ABCB11, SLC10A2, SI | ADORA3 608/4885ATP4A 71/4885ADORA1 408/4885 |
| US-20050182101-A1 | Prodrugs of proton pump inhibitors | ABCB11, SLC10A2, SI | ADORA3 698/4885ATP4A 38/4885ADORA1 469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.